Amphetamine-related Disorders Clinical Trial
Official title:
Behavior Change: Reinforcement Schedule Effects
The purpose of this study is to determine if different reinforcement procedures (i.e., schedules) produce different patterns of long-term abstinence from methamphetamine. We anticipate that the three contingency management conditions will promote longer periods of abstinence in the year following treatment relative to the standard control group. Furthermore, we predict that the intermittent reinforcement procedures will produce longer periods of continued abstinence (i.e., long-term behavior change) in the year following treatment than the continuous reinforcement procedure. Finally, we predict that the intermittent unpredictable schedule will produce longer lasting behavior change than the intermittent predictable schedule. Methamphetamine use will be measured using urine toxicology and self-report of methamphetamine use.
Briefly the four study conditions are: (1) standard treatment which consists of 16 weeks of psychosocial treatment, (2) continuous contingency management which consists of 16 weeks of psychosocial treatment with a contingency management procedure in effect during the first twelve weeks in which vouchers are made available after each provision of a methamphetamine-negative urine test, (3) intermittent predictable contingency management which consists of 16 weeks of psychosocial treatment with a contingency management procedure in effect during the first twelve weeks in which vouchers are available after the provision of every three consecutive methamphetamine-negative urine samples, and (4) intermittent unpredictable contingency management which consists of 16 weeks of psychosocial treatment with a contingency management procedure in effect during the first twelve weeks in which vouchers are available on one day each week (randomly selected after the first week) for the provision of methamphetamine-negative urine samples provided all urine samples since delivery of the last reinforcer were also methamphetamine negative. ;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02232789 -
Abuse Liability and Human Pharmacology of Mephedrone
|
Phase 1 | |
Completed |
NCT01449565 -
Extended-Release Naltrexone to Treat Methamphetamine Dependence in Men Who Have Sex With Men (MSM)
|
Phase 2 | |
Completed |
NCT00247572 -
Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults With Stimulant Abuse Histories
|
Phase 2 | |
Active, not recruiting |
NCT00100074 -
To Assess the Safety and Tolerability of 7.5, 15 and 30 mg of Sublingual Lobeline. - 1
|
Phase 1 | |
Active, not recruiting |
NCT00033072 -
Assessment of Potential Interactions Between Methamphetamine and Selegiline - 1
|
Phase 1 | |
Recruiting |
NCT06145698 -
Treatment Effect of Cross-frequency Transcranial Alternating Current Stimulation on the MUD
|
N/A | |
Completed |
NCT00990067 -
Interaction Between Duloxetine and 3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy)
|
Phase 1 | |
Completed |
NCT02797990 -
Conflict Between Maternal Autonomy and Child Health in Substance-use
|
N/A | |
Recruiting |
NCT01899313 -
A Cognitive Behavioral Therapy-Based Text Message Intervention for Methamphetamine Dependence
|
N/A | |
Active, not recruiting |
NCT00265278 -
Assessment of Interactions Between Intravenous Methamphetamine and Modafinil - 1
|
Phase 1 | |
Active, not recruiting |
NCT00000350 -
Effects of Stimulant Dependence on Human Striatal Dopamine System - 15
|
Phase 1 | |
Active, not recruiting |
NCT00089440 -
Assessment of Interactions Between Methamphetamine and Aripiprazole - 1
|
Phase 1 | |
Active, not recruiting |
NCT00040040 -
Assessment of Potential Interactions Between Methamphetamine and Bupropion - 1
|
Phase 1 | |
Completed |
NCT00040053 -
Ondansetron for the Treatment of Methamphetamine Dependence - 1
|
Phase 2 | |
Completed |
NCT00895804 -
Pharmacological Interaction Between Pindolol and MDMA (3,4-Methylenedioxymethamphetamine)
|
Phase 1 | |
Recruiting |
NCT03902405 -
Computerized Exercise to Alter Stimulant Approach Responses
|
N/A | |
Recruiting |
NCT04982796 -
Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder
|
Phase 1/Phase 2 | |
Completed |
NCT01386177 -
Pharmacological Interaction Between Doxazosin and Methylenedioxymethamphetamine (MDMA)
|
Phase 1 | |
Completed |
NCT01136278 -
Pharmacological Interaction Between Clonidine and Methylenedioxymethamphetamine (MDMA)
|
Phase 1 | |
Completed |
NCT00069251 -
Bupropion for the Treatment of Methamphetamine Dependence - 1
|
Phase 2 |